Nanosynex

Antimicrobial Susceptibility Test

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2017
Last updated 2026-06-18
Total raised
$6.3M
Last: Grant 2025-06
Stage
Seed
Founded
2017
Headcount
8
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Nanosynex is developing solutions designed to improve testing quality and reduce healthcare costs by accelerating diagnostic processes.

Nanosynex is focused on the development and commercialization of an innovative antimicrobial susceptibility test (AST). The technology is based on a purely phenotypic approach and uses a microfluidic disposable test cartridge platform and method that optimizes bacterial growth.

The Nanosynex solution comprises a disposable test platform, hardware, and analysis software. The product will allow laboratories to perform and provide results for same-day antimicrobial susceptibility tests, enabling doctors to create targeted, personalized antibiotic prescriptions for their patients.

The companys technology stems from research discoveries made in the lab of Professor Shulamit Levenberg, dean of the Faculty of Biomedical Engineering at the Technion.

Funding history · 7 rounds · $6.3M total

2025-01
$500K
2019-06
Grant $2.5M
2018-12
2018-11
2018-08
Date unknown
$1.6M

Q&A

What is Nanosynex's primary focus?
Nanosynex is focused on developing and commercializing an innovative antimicrobial susceptibility test (AST) that uses a microfluidic disposable test cartridge platform.
When was Nanosynex founded?
Nanosynex was founded in February 2017.
What is the total amount of funding Nanosynex has raised to date?
Nanosynex has raised a total of $6,340,000 USD.
Which organizations provided grant funding to Nanosynex in June 2025?
In June 2025, Nanosynex received grant funding from Synergy7 and Israel Innovation Authority.
How many employees does Nanosynex currently have?
Nanosynex currently has 1-10 employees.
Who are the co-founders of Nanosynex?
The co-founders of Nanosynex are Diane Abensur, who serves as CEO, and Michelle Heymann, who is VP Marketing & Operations.
What is the origin of Nanosynex's technology?
Nanosynex's technology stems from research discoveries made in the lab of Professor Shulamit Levenberg, dean of the Faculty of Biomedical Engineering at the Technion.
What is Nanosynex's primary sector?
Nanosynex's primary sector is Health Tech & Life Sciences.

Team · 2

Founder · Co-founder & CEO
LinkedIn ↗
Founder · Co-founder & VP Marketing & Operations
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision Support
Technologies
BiologicalsPlatforms & InterfacesSoftware
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

personalized-medicinenon-invasivedetectionnanotechnologylaboratoriesclinicsinfectious-diseasediagnosticshospitalsblood-testmedical-technologiesbacteriahealthcare-providersurologyhardwaresoftware-platformschoolsbiotechnologyairports
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)